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ABSTRACT
Background The 5-aminolevulinic acid (ALA)-based 
photodynamic diagnosis is based on the accumulation 
of photosensitizing protoporphyrin IX in the tumor 
after ALA administration. However, the mechanisms 
connecting exogenous ALA and tumor fluorescence 
in pancreatic cancer remain unclear. We aimed to 
elucidate the mechanism underlying the ALA-induced 
fluorescent.
Methods Human pancreatic duct epithelial cells 
(hPDECs) and pancreatic cancer cell lines were used. 
The expressions of ALA-associated enzymes and mem-
brane transporters in these cell lines were investigated. 
ALA-induced fluorescence was also investigated.
Results The expression of oligopeptide transporter-1 
(PEPT-1), through which ALA is absorbed, was signifi-
cantly higher in AsPC-1 cells and lower in MIA PaCa-
2 cells than in hPDECs. AsPC-1 cells showed rapid and 
intense fluorescence after ALA administration, and that 
was attenuated by PEPT-1 inhibition. ALA-induced 
fluorescence was not sufficiently strong in MIA PaCa-2 
cells to distinguish the cells from hPDECs.
Conclusion We revealed the association of PEPT-1 
with ALA-induced fluorescence. Cancers expressing 
PEPT-1 could be easily distinguished by this technique 
from normal cells. These findings help develop novel 
diagnostic modalities for pancreatic cancer.
Key words fine needle aspiration; oligopeptide trans-
porter-1; pancreatic cancer; photodynamic diagnosis; 
protoporphyrin IX
Pancreatic cancer is one of the leading causes of cancer-
related deaths worldwide. Resection is still the only 
curative treatment for pancreatic cancer, however most 
patients cannot undergo curative resection because 
pancreatic cancer is difficult to detect at an early stage. 
In many cases, the cancer has already locally advanced 
or spread to other parts of the body, therefore cura-
tive resection cannot be performed.1–4 Furthermore, 
the 5-year survival rate after curative resection is 
approximately 15–20%, with a median survival of 
16–23 months.5–8 Although the 5-year survival rate 
in pancreatic cancers at a size of less than 10mm was 
more than 80% in Japan, only 0.8% could be detected at 
this size.9 Therefore, development of a novel diagnostic 
modality for identifying pancreatic cancer at an early 
stage is necessary.
Photodynamic diagnosis (PDD) is an optical 
imaging technology that involves the administration 
of photoactive drugs that selectively accumulate in the 
malignant tumor, resulting in drug-induced fluores-
cence.10, 11 5-aminolevulinic acid (ALA) is a precursor 
of photosensitizing protoporphyrin IX (PpIX) in the 
heme biosynthesis pathway. Exogenously administrated 
ALA increases the cellular PpIX levels, leading to an 
evident emission of red fluorescence at around 635 nm 
in certain tumors compared to the non-tumor surround-
ing tissues with a blue-violet excitation light.10–12 Thus, 
ALA-PDD relies on tumor-specific PpIX accumulation. 
This technique has been applied for the detection of 
bladder and brain tumors.11, 13 However, the utility of 
PDD has not been established for pancreatic cancer.
The heme biosynthesis pathway comprises eight 
consecutive enzymes (Fig. 1): 5-aminolevulinic acid 
synthase (ALAS), porphobilinogen synthase (PBGS), 
porphobilinogen deaminase (PBGD), uroporphy-
rinogen III synthase (UROS), uroporphyrinogen III 
decarboxylase (UROD), coproporphyrinogen oxidase 
(CPOX), protoporphyrinogen IX oxidase (PPOX), and 
ferrochelatase (FECH).14 In addition to these enzymes, 
several transporters are also involved in the biosynthesis 
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and catabolism of heme and porphyrin, including oli-
gopeptide transporter-1 (PEPT-1), and the ATP-binding 
cassette (ABC) transporters ABCB6 and ABCG2. ALA 
is a natural amino acid synthesized in the mitochondria 
from succinyl-CoA and glycine. Exogenous ALA is 
imported into the cytoplasm through PEPT-1 and then 
metabolized to PpIX, which is the final metabolite in the 
heme biosynthesis pathway.15 Accumulation of PpIX in 
the mitochondria would be accelerated by endogenous 
ALA production, exogenous ALA absorption through 
PEPT-1, ALA metabolism by heme biosynthesis 
enzymes and import of ALA metabolite from cytosol 
into mitochondria through ABCB6, whereas it would be 
suppressed by metabolism of PpIX to heme by FECH 
and PpIX elimination through ABCG2. Previous inves-
tigations have revealed that PPOX was highly expressed 
in the ALA-reactive gastric cancer, ref lecting the 
accelerated metabolism of exogenous ALA to PpIX,16 
and that altered expression of PEPT-1 and ABCG2 in 
gastric cancer cells affected intracellular photosensitiz-
ing PpIX levels.17, 18 In addition, PEPT-1 is reported to 
be expressed in pancreatic cancer cell lines,19, 20 and 
ALA uptake is possibly associated with the efficacy of 
PDD.21 However, despite various heme enzymes and 
membrane transporters affect the PpIX accumulation 
within the mitochondria, the detailed mechanism of ac-
cumulation of this metabolite in pancreatic cancer cells 
remains unclear. Therefore, we aimed to investigate the 
molecular mechanisms that influence the fluorescence 
in ALA-PDD, in particular, the enzymes and membrane 
transporters involved in the heme biosynthesis pathway 
in human pancreatic cancer cells.
MATERIALS AND METHODS
Cell lines and cell culture
Immortalized human pancreatic duct epithelial 
cells (hPDECs) (Applied Biological Materials Inc., 
Richmond, Canada) and the human pancreatic cancer 
cell lines MIA PaCa-2, AsPC-1, BxPC-3, SUIT-2, KP-4, 
KP-3L, TYPK-1 (The Japanese Collection of Research 
Bioresources, Tokyo, Japan), Capan-1 (Cell Lines 
Service GmbH, Eppelheim, Germany), and PANC-1 
(The European Collection of Cell Cultures, Salisbury, 
UK) were used in this study. hPDECs were maintained 
in Prigrow I medium supplemented with 20% fetal 
bovine serum (FBS). AsPC-1, BxPC-3, KP-3L, and 
Capan-1 cells were maintained in RPMI 1640 medium 
supplemented with 10% FBS. MIA PaCa-2 cells were 
maintained in RPMI 1640 medium supplemented 
with 10% FBS and non-essential amino acids. SUIT-
2 cells were maintained in Eagle’s minimal essential 
medium supplemented with 10% FBS. KP-4 cells were 
maintained in Iscove’s Modified Dulbecco’s Medium 
supplemented with 20% FBS. PANC-1 cells were 
Fig. 1. Scheme of the heme biosynthesis pathway and membrane transporters. ALA is synthesized from glycine and succinyl CoA 
endogenously or exogenously absorbed through PEPT-1. Protoporphyrin IX synthesized from ALA via enzymatic reactions, then 
catabolized to heme by FECH or eliminated through ABCG2. ABC, ATP-binding cassette; ALA, 5-aminolevulinic acid; ALAS, 5-ami-
nolevulinic acid synthase; CPOX, coproporphyrinogen oxidase; FECH, ferrochelatase; PBGD, porphobilinogen deaminase; PBGS, 
porphobilinogen synthase; PEPT-1, oligopeptide transporter-1; PPOX, protoporphyrinogen IX oxidase; UROD, uroporphyrinogen III 
decarboxylase; UROS, uroporphyrinogen III synthase.
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maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS. TYPK-1 cells 
were maintained in F12/DMEM supplemented with 5% 
FBS. All media contained 1% L-glutamine. Cells were 
cultured in tissue culture dishes at 37°C in a humidified 
atmosphere of 95% air and 5% carbon dioxide.
Gene expression analysis
Total RNA was extracted from the cells using the 
miRNeasy Mini Kit (QIAGEN Co., Ltd., Tokyo, Japan) 
following the manufacturer’s instructions. The concen-
trations of all RNA samples were quantified using the 
NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific Inc., Tokyo, Japan). Extracted RNA samples 
were stored at –80°C until further use. The cDNA was 
prepared from total RNA using the High Capacity 
cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific Inc., Tokyo, Japan). The reverse transcription 
(RT) reactions were performed in aliquots containing 
3000 ng of total RNA, 1× RT buffer, 6 mM dNTP mix, 
1× RT random primer, 75 units of MultiScribe Reverse 
Transcriptase, 30 units of RNase inhibitor, and nuclease-
free water in a volume of 30 μL at 25°C for 10 min, 
followed by an incubation at 37°C for 120 min and 85°C 
for 5 min. A quantitative PCR reaction was performed 
in 20-μL aliquots containing 1 μL of RT products with 4 
μL of LightCycler® FastStart DNA MasterPLUS SYBR 
Green I (Roche Diagnostics Co., Ltd., Tokyo, Japan), 0.5 
μM of each primer, and 14.6 μL of nuclease-free water 
in the Real-time PCR LightCycler 1.5 Complete System 
(Roche Diagnostics Co., Ltd., Tokyo, Japan). mRNA 
levels of PBGS, PBGD, UROS, UROD, CPOX, PPOX, 
FECH, PEPT-1, ABCB6, and ABCG2 were measured 
by performing quantitative RT-PCR. Thermal cycling 
was initiated with a first denaturation step at 95°C for 10 
min, followed by 45 cycles of 95°C for 10 s, 60°C for 10 s, 
and 72°C for 10 s. The cycle passing threshold (Ct) was 
recorded for mRNA by the LightCycler Software ver-
sion 3.5.28 (Roche Diagnostics Co., Ltd., Tokyo, Japan), 
and β-actin was used as the endogenous control for 
data normalization. Relative expression was calculated 
using the formula 2–ΔΔCt = 2 – (ΔCt, reagent treat-
ment – ΔCt, control).22 The forward and reverse primer 
sequences used in this study are summarized in Table 1.
Western blot analysis
The rabbit polyclonal anti-PEPT-1 antibody (Abcam 
PLC., Tokyo, Japan), rabbit monoclonal anti-β-actin 
(D6A8) antibody (CST Japan Co., Ltd, Tokyo, Japan), 
and horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit IgG H&L (Abcam PLC., Tokyo, Japan) 
were used. Cultured cells were directly lysed for 15 
min on ice using the RIPA Lysis and Extraction Buffer 
(Thermo Fisher Scientific Inc., Tokyo, Japan) contain-
ing cOmplete™ ULTRA Tablets, Mini, EASYpack 
Protease Inhibitor Cocktail and PhoSTOP (Roche 
Diagnostics Co., Ltd., Tokyo, Japan). After centrifuga-
tion at 21,500 × g for 15 min, protein concentrations 
were measured using the Pierce 660 nm Protein Assay 
Reagent (Thermo Fisher Scientific Inc., Tokyo, Japan), 
and the protein was denatured by boiling for 5 min. The 
extracted proteins were loaded onto sodium dodecyl 
sulfate-polyacrylamide gels for electrophoresis and 
then transferred onto nitrocellulose membranes. After 
Table 1. Primer sequences for quantitative reverse transcription-PCR
Symbol Forward primer Reverse primer
PEPT-1 5’- TCACCTGTGGCGAAGTGGTC -3’ 5’- GCCACGATGAGCACAATGATG -3’
ABCB6 5’- TTCACTGTGATGCCTGGACAGA -3’ 5’- GGATGCAGCCAGAGCTGATG -3’
ABCG2 5’- GCAACCATCAATTCAGGTCAAGA -3’ 5’- GAAACACAACACTTGGCTGTAGCA -3’
PBGS 5’-AACCAGCATAAATACTGCCTGAGGA -3’ 5’- TGGCACCTCTAGCAGTCAGGAA -3’
PBGD 5’-AACAGCCCAAAGATGAGAGTGATTC -3’ 5’- AATGTTGCCACCACACTGTCC -3’
UROS 5’- CCTGAACAGCTACTATTCCGAGCA -3’ 5’- CTTGAGACTGTATGTGAGGCCAGAG -3’
UROD 5’- CCCTGTGCCTTGTATGCATCTG -3’ 5’- TGTAGCGATGTGGTCCAAAGTCA -3’
CPOX 5’- CACTCCAGGATCCAGAATTGAAAG -3’ 5’- TGCATCAACGCACCCAGTC -3’
PPOX 5’- GCCCTTGAAACCCACCTGACTA -3’ 5’- ACTAATAACGTGGTCAGCCTCCAGA -3’
FECH 5’- AGGCCATTAAGATGGATGTTGGAA -3’ 5’- CTGTCAGAGTGAAGGCTCACAAGAA -3’
β-actin 5’- GCATCCTCACCCTGAAGTA -3’ 5’- TGTGGTGCCAGATTTTCTCC -3’
ABC, the ATP-binding cassette; CPOX, coproporphyrinogen oxidase; FECH, ferrochelatase; PBGD, porphobilinogen deaminase; 
PBGS, porphobilinogen synthase; PEPT-1, oligopeptide transporter-1; PPOX, protoporphyrinogen IX oxidase; UROD, uroporphy-
rinogen III decarboxylase; UROS, uroporphyrinogen III synthase.
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blocking with 5% milk in TBST (150 mmol/L NaCl 
and 50 mmol/L Tris-HCl containing 0.05% Tween-20), 
the membranes were incubated with anti-PEPT-1 (1:500 
dilution) or anti-β-actin (1:1000 dilution) antibodies at 
4°C overnight. After washing with TBST 3 times (5 min 
each), the membranes were incubated with their cor-
responding HRP-conjugated secondary antibodies (for 
PEPT-1, 1:5000 dilution; for β-actin, 1:20,000 dilution) 
at room temperature for 1 h. After washing with TBST 
3 times (5 min each), the bound antibodies were visual-
ized using the Clarity Western ECL Substrate (Bio-Rad 
Laboratories, Inc., Tokyo, Japan) and an image analyzer 
(LAS-3000 mini, Fujifilm Co. Ltd., Tokyo, Japan). The 
band intensities were quantified using the Multi Gauge 
Ver. 3.1 (Fujifilm Co. Ltd., Tokyo, Japan).
Incubation of cells with ALA
ALA hydrochloride (Cosmo Bio Co., Ltd., Tokyo, Japan) 
was added to the culture medium and the cells were 
incubated in the dark. The cells were then harvested 
for RNA quantification or examined for fluorescence 
analyses. Fluorescence was examined using a BZ-X710 
microscope (Keyence, Osaka, Japan) with an excitation 
wavelength of 405 nm, and fluorescence detection at 
630 nm, with a 40× objective. Fluorescence intensity 
after ALA administration was quantified as previously 
described.23 In brief, all detectable cells were outlined, 
and the intensity of each cell was analyzed using ImageJ 
software (U. S. National Institutes of Health, Bethesda, 
MD). Fluorescence intensity as reported was an average 
of the intensities of all analyzed cells. For the transporter 
inhibition experiment, P-(aminomethyl) benzoic acid 
(AMBA; FUJIFILM Wako Pure Chemical Co., Ltd., 
Osaka, Japan), a PEPT-1 inhibitor, was added to the 
culture medium to a final concentration of 30 mM.
Statistical analysis
The expression levels of mRNA for enzymes and trans-
porters were analyzed by one-way analysis of variance 
(ANOVA) with post hoc Dunnett test. The unpaired t 
test was performed to assess the differences in mRNA 
expressions after ALA administration. The differences 
in signal intensities in western blot analysis and fluo-
rescent intensities between each group were analyzed 
by one-way ANOVA with post hoc Tukey test. P values 
less than 0.05 were considered as significant. StatFlex 
(Windows ver. 6.0; Arthech, Osaka, Japan) was used for 
the statistical analysis. All values are expressed as the 
mean ± SEM.
RESULTS
mRNA expression of heme biosynthesis enzymes 
and membrane transporters
Most of the mRNA expression levels of the heme 
biosynthesis enzymes were higher in pancreatic cancer 
cells than in hPDEC cells; however, variations in the 
Fig. 2. mRNA expression of heme biosynthesis enzymes in hPDECs and pancreatic cancer cells. The relative mRNA expression 
levels of the enzymes including PBGS, PBGD, UROS, UROD, CPOX, PPOX, and FECH were assessed using quantitative reverse 
transcription-polymerase chain reaction in hPDECs and pancreatic cancer cells. The relative levels of enzymes compared to those of 
hPDECs are shown with a logarithmic scale. Bars indicate average ± SEM. # P < 0.05, *P < 0.01 compared to the expression levels in 
hPDECs analyzed by one-way ANOVA followed by post hoc Dunnet test. CPOX, coproporphyrinogen oxidase; FECH, ferrochelatase; 
hPDEC, human pancreatic duct epithelial cell; PBGD, porphobilinogen deaminase; PBGS, porphobilinogen synthase; PPOX, protopor-
phyrinogen IX oxidase; UROD, uroporphyrinogen III decarboxylase; UROS, uroporphyrinogen III synthase.
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mRNA levels among cancer cells were relatively small 
(Fig. 2). mRNA expression of membrane transporters, 
in particular for PEPT-1, in pancreatic cancer cells 
showed remarkable differences; PEPT-1 levels were 
significantly higher in AsPC-1, SUIT-2 and KP-3L than 
in hPDECs and showed lower trend in MIA PaCa-2, 
BxPC-3, KP-4, TYPK-1 and PANC-1 than in hPDECs 
(Fig. 3A). Most of the cancer cells, except for MIA 
PaCa-2, showed higher levels of ABCG2 (Fig. 3B). The 
expressions of ABCB6 were low in all the pancreatic 
cancer cells compared to hPDECs (Fig. 3C).
Protein expression of PEPT-1
As PEPT-1 could be involved in PpIX overexpression,14 
we further investigated the protein levels of PEPT-1 in 
the hPDECs, MIA PaCa-2, and AsPC-1 cells, which 
showed remarkable differences in the quantitative RT-
PCR analyses. PEPT-1 was abundantly expressed in 
AsPC-1 cells compared to the expression in hPDECs, in 
contrast to the weak expression in MIA PaCa-2 cells (Fig. 
4A). Quantitative analysis of the western blot revealed 
that the difference between hPDECs and AsPC-1 cells 
was significant (Fig. 4B).
Fluorescence after incubation with ALA
The results from quantitative RT-PCR and western blot 
suggested that the increased expression of PEPT-1 could 
reveal key mechanisms in ALA-PDD. Therefore, we 
investigated the fluorescence in hPDECs, MIA PaCa-2 
and AsPC-1 cells after ALA administration. The fluo-
rescence was analyzed in the time course at 1, 2, and 4 h 
after ALA administration (Fig. 5). AsPC-1 cells, which 
highly expressed PEPT-1, showed a stronger and rapid 
induction of fluorescence than hPDECs or MIA PaCa-2 
cells. This result suggests that the ability to distinguish 
cancer cells and hPDECs was stronger at an earlier 
Fig. 3. mRNA expression levels of membrane transporters. The 
relative mRNA expression levels of (A) PEPT-1, (B) ABCG2, and 
(C) ABCB6 assessed using quantitative reverse transcription-
polymerase chain reaction in hPDECs and pancreatic cancer 
cells. The relative levels compared to hPDECs are shown with 
a logarithmic scale. Bars indicate average ± SEM. *P < 0.01 
compared to the expression levels in hPDECs analyzed by one-
way ANOVA followed by post hoc Dunnet test. ABC, the ATP-
binding cassette; hPDEC, human pancreatic duct epithelial cell; 
PEPT-1, oligopeptide transporter-1.
Fig. 4. Protein expression levels of PEPT-1 in hPDECs, MIA 
PaCa-2, and AsPC-1 cells. (A) Representative image of western 
blot for PEPT-1 and β-actin in hPDECs, MIA PaCa-2, and AsPC-
1 cells. (B) Quantitative analyses of the western blots for PEPT-1 
protein from 3 repetitive experiments. The signal intensity was 
normalized to the β-actin protein level and expressed as relative 
expression levels in hPDECs. Bars indicate average ± SEM. *P < 
0.05 compared to hPDECs. One-way ANOVA followed by post 
hoc Tukey test. hPDEC, human pancreatic duct epithelial cell; 
PEPT-1, oligopeptide transporter-1.
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time-point. Inhibition of PEPT-1 by AMBA attenuated 
PpIX accumulation in all the cells, especially in AsPC-
1 cells (Fig. 6). Since several cell lines other than AsPC-
1 showed high mRNA expression of PEPT-1 as well, we 
further investigated the PpIX accumulation in the other 
cell lines. The cell lines with relatively high expression 
of PEPT-1 such as SUIT-2, KP-3L, and Capan-1 showed 
intense fluorescent compared to the other cell lines with 
relatively low expression of PEPT-1 such as BxPC-3, 
KP-4, TYPI-1, and PANC-1 (Fig. 7).
DISCUSSION
In this study, we demonstrate that PEPT-1, which regu-
lates the cellular intake of ALA, was highly expressed 
in AsPC-1 cells compared to the expression in hPDECs 
or the pancreatic cancer cell lines MIA PaCa-2. AsPC-1 
cells showed intense fluorescence after ALA adminis-
tration, which was attenuated by the PEPT-1 inhibitor. 
Pancreatic cancer cells expressing high level of PEPT-1 
showed strong fluorescent by the administration of 
ALA. These data suggest that PEPT-1 was associated 
with the intensity of ALA-induced f luorescence in 
pancreatic cancer cells.
ALA-PDD is a promising diagnostic modality for 
diagnosing cancers. This technique was applied in the 
diagnosis of bladder, brain, and gastric tumors,11, 13, 16 
and is expected to contribute to the early diagnosis of 
pancreatic cancer. Harada et al. reported that ALA-PDD 
was useful for detecting peritoneal metastasis during 
staging laparoscopy in patients with pancreatic cancer.24 
The diagnosis of pancreatic cancer at an early stage is 
still challenging, and the development of a new modality 
for a more accurate diagnosis is needed. Cytodiagnosis 
or histological diagnosis using endoscopic ultrasound-
guided fine needle aspiration (EUS-FNA) is one of 
the modalities that can be utilized for the early and 
accurate diagnosis of pancreatic cancer. EUS-FNA 
usually requires an on-site review by a cytopathologist 
Fig. 5. Fluorescence in hPDECs, MIA PaCa-2, and AsPC-1 cells after incubation with ALA. (A) Representative images of 
fluorescence in hPDECs, MIA PaCa-2, and AsPC-1 cells at baseline, 1, 2, and 4 h after ALA administration. ALA was ad-
ministered at final concentrations of 0.25 mM. Bar = 100 μm. (B) Fluorescence intensities were quantified and represented as 
the relative intensity to hPDECs. Bars indicate average ± SEM. **P < 0.01 (one-way ANOVA with post hoc Bonferroni test). 
ALA, 5-aminolevulinic acid; hPDEC, human pancreatic duct epithelial cell.
160
H. Kinoshita et al.
© 2020 Tottori University Medical Press
or cytotechnician. Although the diagnostic accuracy 
relies on the adequacy of the samples, a cytopathologist 
or cytotechnician cannot always stay on-site during 
the procedure to review the samples. EUS-FNA using 
ALA-PDD may allow for diagnosing pancreatic cancer 
more easily. The underlying mechanism for the tumor-
specific fluorescence has not been fully understood. 
Therefore, it will contribute to the accurate diagnosis or 
detection of pancreatic cancer to elucidate the mecha-
nism of ALA-PDD in pancreatic cancer cells.
In the present study, we investigated the associa-
tion of heme metabolism enzymes and transporters 
to ALA-PDD in pancreatic cancer cells. In contrast 
to the small variations in expression level of heme 
enzymes, membrane transporters such as PEPT-1 and 
ABCG2 showed significant differences among the 
cancer cell lines. Both of these two transporters were 
highly expressed in AsPC-1 cells, and weakly expressed 
in MIA PaCa-2 cells compared to the normal cells. 
Therefore, we hypothesized that a comparison of PpIX 
accumulation in these cell lines would reveal the rele-
vant transporters mediating PpIX accumulation; PEPT-1 
would be dominant if PpIX accumulation was high in 
AsPC-1 cells, and ABCG2 would be dominant if PpIX 
accumulation was low in AsPC-1 cells. Upon ALA 
administration, AsPC-1 cells showed rapid induction 
and intense fluorescence, indicating a considerable role 
of PEPT-1 in ALA-mediated PpIX accumulation. The 
influence of endogenous ALA production on ALA-PDD 
could be ignored, because the fluorescence was almost 
undetectable in the absence of ALA administration. We 
have also investigated the PpIX accumulation in all the 
pancreatic cancer cell lines. The cell lines with relatively 
high expression of PEPT-1 showed intense fluorescent 
after ALA administration, suggesting that PEPT-1 plays 
an important role in accumulation of PpIX in pancreatic 
cancer. We further confirmed the relationship of PEPT-1 
and ALA-mediated PpIX accumulation using the 
PEPT-1 inhibitor AMBA, which attenuated PpIX ac-
cumulation especially in AsPC-1. In a previous report, 
FECH has been reported to enhance the fluorescence 
after the administration of ALA.25 Since the expression 
of FECH was higher in MIA PaCa-2 than in AsPC-
1 in this study, we could not eliminate the influence 
of FECH to the difference between AsPC-1 and MIA 
PaCa-2. However, we revealed that the fluorescence 
in hPDECs and AsPC-1 remarkably differ despite 
the nearly similar expression levels of FECH in these 
two cell lines. Therefore, we consider the influence of 
FECH to the ALA-induced fluorescence is relatively 
weak compared to PEPT-1. Previous investigations in 
gastric cancer showed the relationship between PPOX 
and ALA-induced f luorescence.16 The expressions 
level of PPOX in pancreatic cancer is similar to that in 
gastric cancer, therefore PPOX might affect the PpIX 
accumulation in AsPC-1 as well.26 However, as we have 
discussed above, exogenously administered ALA and 
ALA absorption through PEPT-1 play an important role 
in ALA-induced PDD in pancreatic cancer. Together 
with the fact that MIA PaCa-2 cells, which expressed 
relatively low level of PEPT-1, showed weak induction 
of fluorescence suggests that ALA-PDD depends on 
the membrane transporters expressed in each cancer. 
AsPC-1 derives from metastatic pancreatic cancers, 
while MIA PaCa-2 cells derives from pancreatic tumor 
tissue. We speculate that the expression levels of PEPT-1 
depend on the degree of malignancy. In fact, it has been 
proved that PEPT-1 promotes the progression or prolif-
eration of pancreatic cancer.27 Further investigations, 
Fig. 6. PpIX accumulation in hPDECs, MIA PaCa-2, and 
AsPC-1 cells incubated with ALA and the PEPT-1 inhibitor 
P-(aminomethyl) benzoic acid. (A) Representative images of fluo-
rescence in hPDECs, MIA PaCa-2, and AsPC-1 cells after ALA 
administration with or without AMBA at a final concentration of 
30 mM. Bar = 200 μm. (B) Quantitative analyses for fluorescence 
intensities in hPDECs, MIA PaCa-2, and AsPC-1 cells, expresses 
as the relative intensity to hPDECs without AMBA. Bars in dicate 
average ± SEM. *P < 0.05, ***P < 0.001 (Mann-Whitney U test 
in each cell line). ALA, 5-aminolevulinic acid; hPDEC, human 
pancreatic duct epithelial cell.
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especially with clinical samples, are required to apply 
this technique to clinical specimens.
There were some limitations in this study. Some 
porphyrins synthesized in the ALA-to-PpIX pathway 
might also emit fluorescence, thereby influencing the 
results. However, the f luorescence spectrum of the 
porphyrin intermediate metabolite is different from that 
of PpIX. This discrepancy in the spectrum has been 
applied in the diagnosis of porphyria.28 Expression 
levels of heme enzymes among the cancer cell lines 
were not downregulated. Therefore, we assumed that 
the influence of fluorescence from the other porphyrins 
was negligible. ABCG2, an exporter of PpIX, may be 
another factor for ALA-induced fluorescence. However, 
as we have discussed above, the fluorescence was re-
markably stronger in AsPC-1 compared to MIA PaCa-
2 cells, suggesting that PEPT-1 contributed dominantly 
to the ALA-induced PpIX accumulation. We did not 
measure the expression level of ALAS, which mediates 
endogenous ALA production. However, endogenous 
ALA production or the expression of ALAS could be 
ignored because of the faint autofluorescence observed 
in the absence of ALA.
In conclusion, we report a new finding for the 
mechanism of ALA-PDD in pancreatic cancer cells. 
Cells with high expression levels of PEPT-1 could be 
easily distinguished from normal cells via ALA admin-
istration. These findings contribute to the development 
of a novel diagnostic modality, ALA-PDD, for pancre-
atic cancer.
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